Adagene Presents at ESMO Congress in September 2024

Ticker: ADAG · Form: 6-K · Filed: 2024-09-16T00:00:00.000Z

Sentiment: neutral

Topics: press-release, conference-presentation, regulatory-filing

TL;DR

Adagene presented at ESMO Congress, check the press release for deets.

AI Summary

Adagene Inc. filed a Form 6-K on September 16, 2024, to report its activities for the month of September 2024. The filing includes a press release titled "Adagene Presents Results at ESMO Congress," indicating the company shared its findings at this significant oncology event. The report is filed under the Securities Exchange Act of 1934, with Peter Luo, CEO, signing on behalf of the company.

Why It Matters

This filing signals Adagene's active participation in major scientific conferences, potentially highlighting new research or clinical data that could impact its drug development pipeline and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine report of a press release and does not contain new financial information or significant corporate events that would immediately alter risk.

Key Players & Entities

Adagene Inc. (company) — Registrant
September 16, 2024 (date) — Filing Date
Peter Luo (person) — Chief Executive Officer
ESMO Congress (event) — Conference where results were presented

FAQ

What specific results did Adagene present at the ESMO Congress?

The filing mentions a press release titled "Adagene Presents Results at ESMO Congress," but the specific results are not detailed within this 6-K form itself. The press release would contain this information.

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC to provide information that the issuer has made or is required to make public pursuant to the laws of its home country or that it has filed or will file with a stock exchange.

Who signed this Form 6-K on behalf of Adagene Inc.?

Peter Luo, the Chief Executive Officer of Adagene Inc., signed the Form 6-K on September 16, 2024.

What is Adagene Inc.'s principal executive office address?

Adagene Inc.'s principal executive offices are located at 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, 215123, People's Republic of China.

Does Adagene Inc. file annual reports under Form 20-F or Form 40-F?

Adagene Inc. indicates it files annual reports under cover of Form 20-F.

From the Filing

0001104659-24-100046.txt : 20240916 0001104659-24-100046.hdr.sgml : 20240916 20240916092110 ACCESSION NUMBER: 0001104659-24-100046 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240916 FILED AS OF DATE: 20240916 DATE AS OF CHANGE: 20240916 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adagene Inc. CENTRAL INDEX KEY: 0001818838 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39997 FILM NUMBER: 241299759 BUSINESS ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 BUSINESS PHONE: 86-512-87773632 MAIL ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 6-K 1 tm2424109d1_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a- 16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-512-8777-3632 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨ SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. VNET Group, Inc. By: /s/ Peter Luo Name: Peter Luo Title: Chief Executive Officer Date: September 16, 2024 EXHIBIT INDEX Exhibit Description 99.1 Press release tilted “Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ® ADG126 (Muzastotug) in Combination with KEYTRUDA ® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)” EX-99.1 2 tm2424109d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ® ADG126 (Muzastotug) in Combination with KEYTRUDA ® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab - - Median progression-free survival of 8.5 months observed in patients without liver and peritoneal metastases at the ADG126 10 mg/kg Q3W dose - - At the 10 mg/kg dose level, 12-month overall survival (OS) rates were 74% for patients without liver metastases, and 82% for those without liver and peritoneal metastases - - Safety profile maintained, with only 16% Grade 3 TRAEs in patients treated with ADG126 10 mg/kg Q3W in combination with pembrolizumab - - Combination shows potential with standard of care to address broader patient populations, including MSS CRC patients with liver metastases - SAN DIEGO and SUZHOU, China, September 16, 2024-- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced new ADG126 clinical data presented at the ESMO Congress, taking place in Barcelona, Spain, September 13-17. The poster, titled Increased Therapeutic Index of Muzastotug (ADG126), a Masked Anti-CTLA-4 Antibody, in Combination with Pembrolizumab (Pembro) Enables Significant Clinical Benefits and Supports Further Clinical Development in Patients with Metastatic MSS CRC, reports data